2
Gerresheimer partners with RxCap to offer connected adherence solutions
more
Stories about Pharmakologie
Bosch Healthcare Solutions GmbH
Additional partnership in medical technology: Bosch and R-Biopharm to strengthen Vivalytic analysis platform
Darmstadt, Gerlingen, and Waiblingen, Germany (ots) - Plans to use innovative Bosch BioMEMS technology in PCR tests for multiresistant bacteria - Bosch and R-Biopharm are jointly investing 150 million euros in the development of new PCR tests and in marketing. - PCR test for multiresistant gram-negative (MRGN) ...
moreDr. Reddy's subsidiary betapharm, and Theranica launch Nerivio® in Germany to provide patients with drug-free migraine treatment
moreFennec Pharmaceuticals and Norgine Enter into Exclusive Licensing Agreement to Commercialize PEDMARQSI in Europe, Australia, and New Zealand
Research Triangle Park, N.C. and Uxbridge, England (ots/PRNewswire) - Agreement pairs Norgine's commercial expertise and leading European footprint with PEDMARQSI™, the first and only approved therapy in the European Union and U.K. for reducing the risk of cisplatin-induced hearing loss in pediatric patients with ...
morePress release: STADA continues with double-digit sales and profit growth in 2023
One documentmoreResearch Success in Rare Disease / RHEACELL receives positive signal for accelerated stem cell development program in rare ‚Butterfly Disease‘
more
LTS Lohmann Therapie-Systeme AG
First product based on LTS’ Sorrel(TM) wearable drug delivery platform launched in the US
moreRising Focus on 'Inceptor' as a Type 2 Diabetes Therapeutic Target
moreTherapeutic Vaccine for Chronic Hepatitis B Enters Clinical Trial
moreHearing loss company Acousia announces first patient enrolled in its Phase 2 PROHEAR-Study
Tübingen, Germany (ots) - Acousia Therapeutics GmbH, a Tübingen-based clinical stage biotech company focused on the enhancement and preservation of natural hearing, just announced the randomization of the first patient for the PROHEAR-Study. The PROHEAR-Study is a placebo-controlled, Phase 2a study with split-body design, which investigates the otoprotective efficacy ...
moreBiomay Announces its Successful Support of Approval of First CRISPR/Cas9-based Therapy
moreSHL Medical partners with SteriPack Group to set up final assembly service
more
Press release: STADA and Alvotech secure approval for Uzpruvo, Europe’s first ustekinumab biosimilar to Stelara
STADA and Alvotech secure approval for Uzpruvo, Europe’s first ustekinumab biosimilar to Stelara - Marketing authorization issued in European Economic Area for Uzpruvo®, the first biosimilar to Stelara®, a biologic therapy within ...
One documentmorePress release: Zuellig Pharma becomes STADA Philippines’ exclusive distribution partner
One documentmoreAcousia Therapeutics attracts new investor on its path to make hearing loss a treatable disease
Tübingen (ots) - - German pioneer biotech accelerates hearing loss solution development with fresh capital boost Acousia Therapeutics GmbH, a clinical-stage biotech company developing drug candidates against acute and chronic forms of hearing loss, proudly announces Esperante Ventures as the latest addition to its esteemed group of investors. The infusion of fresh ...
moreLTS Lohmann Therapie-Systeme AG
LTS receives $4.3 Million grant for the development of contraceptive Microneedle Array Patches
moreLTS Lohmann Therapie-Systeme AG
LTS receives grant of $1.2 Million to support the development of thermostable mRNA formulations for Microneedle Array Patches
moreFraunhofer-Institut für Produktionstechnologie IPT
Pooling expertise: Fraunhofer IPT and Harro Höfliger cooperate in the manufacturing of ATMP production systems
more
Press release: STADA strikes partnership with CR Sanjiu in China to drive growth of its cough and cold portfolio
One documentmoreTakeda Pharma Vertrieb GmbH & Co. KG
The European Commission Approves Label Update for TAKHZYRO® (lanadelumab), Expanding Its Use to a Broader Group of Paediatric Patients with Recurrent Attacks of Hereditary Angioedema (HAE)
Zurich (ots/PRNewswire) - - TAKHZYRO® is the First Routine Prevention Treatment of HAE Approved in the EU for Patients Under the Age of Six. - The therapeutical indication for TAKHZYRO® has been extended to patients aged 2 years and older.1 - Offers a New Preventative Treatment Option for young HAE patients with ...
moreBiomay Announces Expansion of GMP-Facilities to Offer mRNA Manufacturing and Aseptic Filling Services
moreUnderstanding the Role of GIP in Managing Diabetes and Obesity
The increasing amount of patients with obesity and type 2 diabetes benefit greatly from the recently developed GIPR:GLP-1R co-agonists. These novel compounds lead to substantial weight loss, offering a revolutionary approach to patients worldwide. Although the hormone glucose-dependent insulinotropic polypeptide (GIP) was already shown by Helmholtz Munich scientists to decrease body weight via the brain GIP receptor, the ...
moreSHL Medical and Lifecore Biomedical enter co-marketing partnership agreement
moreHearing Loss Company Acousia Therapeutics Green Lighted for Game-Changing Phase 2 Trial
Tübingen, Germany (ots/PRNewswire) - Acousia Therapeutics, a pioneer clinical-stage biotech company focused on the development of novel drug therapies for the prevention and treatment of acute and chronic forms of hearing loss, received approval from the German regulatory authorities (BfArM) for its groundbreaking Phase 2 clinical trial of the etiology-agnostic ...
more
Hearing Loss Company Acousia Therapeutics Green Lighted for Game-Changing Phase 2 Trial
Tübingen, Germany (ots) - Acousia Therapeutics, a pioneer clinical-stage biotech company focused on the development of novel drug therapies for the prevention and treatment of acute and chronic forms of hearing loss, received approval from the German regulatory authorities (BfArM) for its groundbreaking Phase 2 clinical trial of the etiology-agnostic otoprotectant ...
moreGerresheimer at CPHI: focus on high-value solutions and sustainability
Duesseldorf (ots) - - Gerresheimer presents an extensive portfolio of containment solutions, drug delivery systems and digital therapy support - High-quality ready-to-fill solutions for biopharmaceuticals, cell and gene therapy - EcoDesign and environmentally friendly packaging options ensure greater sustainability Gerresheimer, an innovative system and solution ...
moreTakeda Pharma Vertrieb GmbH & Co. KG
Takeda Receives Positive CHMP Opinion Recommending Approval of Lanadelumab for Routine Prevention of Recurrent Attacks of Hereditary Angioedema (HAE) in Patients Aged 2 years and Older
Zurich (ots/PRNewswire) - - If Approved, Lanadelumab Will be the First Long-Term Prophylactic Treatment of HAE Available in the EU for Patients Under the Age of Six. - Positive Opinion Based on Pivotal Study SHP643-301, Evaluating the Safety Profile and Pharmacokinetics (PK) of Lanadelumab, in Combination with ...
more- 2
Press release : People with Parkinson’s experience variations in effects of oral medicines, but lack advice, international survey reveals
One documentmore Hearing loss company Acousia Therapeutics to present key learnings and data from lead development programs at US and European meetings in August and September
Tübingen, Germany (ots) - Acousia Therapeutics GmbH to share key learnings and data from its lead candidate development programs — clinical stage ACOU085 and late preclinical stage ACOU082 — during four presentations at industry and research meetings from August 29 to September 5. From August 29–31, Acousia ...
more- 2
Press release: STADA's excellent results in H1 2023 indicate a record annual profit of €1 bn, driven by Consumer Healthcare and Specialty
One documentmore
Previous123456Next